In addition to reduction in antibiotic costs, further cost savings from potential reductions in length of stay and associated critical care costs have not been analysed here. However, based on the costs of intensive care bed days these could run to many thousands (Groves, 2010). The argument that there are benefits in terms of financial costs, reductions in associated morbidity and mortality with VAP prevention are well made elsewhere (NICE, 2008). However, even limited analyses here demonstrate that small costs in terms of antiseptic products and time spent changing clinical care are worthwhile.